CANNA-TICS: Efficacy and Safety of Nabiximols in the Treatment of Adults with Chronic Tic Disorders

Martina Haas1, Anna Pisarenko1, Eva Beate Jenz2, Alexander Brunauer4, Caroline Fremer1, Evgeni Jakubowski1, Daniela Ihlenburg-Schwarz3, Camelia-Lucia Cimpaniu1, Richard Musil3, Alexander Münchau1, Irene Neuner1,2,2, Daniel Hyus2, Ludger Tebarz von Elst3,4, Ammi Koch1, Anika Großenhain1, Kirsten R. Müller-Vahl1

1 Clinic of Psychiatry, Social Psychiatry and Psychotherapy, Kiel University Hospital, Kiel, Germany; 2 Institute of Pharmacology, Bioclinical Research, University of Kiel, Kiel, Germany; 2 Institute of Pharmacology and Psychotherapy, Ludwig-Maximilians University of Munich, Munich, Germany; 3 Department of Neuropsychiatry, Klinikum Kiel, Kiel, Germany; 4 Psychological Hospital, Kiel, Germany; 5 Institute of Systems Marine Sciences, University of Lübeck, Lübeck, Germany; 6 Institute of Neuroscience and Medicine (INM-4), Forschungszentrum Jülich, Jülich, Germany; 7 MPA-RN – Translational Medicine, Aachen, Germany; 8 Department of Psychiatry and Psychotherapy, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany; 9 Department of Psychiatry and Psychotherapy, Medical Centre of University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

Background
New treatment strategies are urgently needed for patients with Tourette Syndrome (TS) and chronic tic disorders (CTD), since current first-line therapies have several limitations. Based on case studies and two small randomized controlled trials (RCT), it has been suggested that cannabis-based medicines might be a promising new treatment option resulting not only in a reduction of tics, but also in an improvement in a variety of comorbidities such as attention deficit/hyperactivity disorder (ADHD). This study aimed to examine for the first time efficacy and safety of the cannabis extract nabiximols (a complex botanical mixture containing THC, CBD, and other cannabinoid and non-cannabinoid components that was provided by GW Pharmaceuticals Ltd) in an investigator-initiated, multicenter, placebo-controlled, parallel-group, phase IIb RCT funded by the German Research Foundation (DFG).

Criteria for Inclusion

- Age ≥18 years
- Total Tic Score of the Yale Global Tic Severity Scale (YGTSS-TTS) > 14 for patients with TS or YGTSS-TTS > 10 for patients with chronic motor or vocal tics only
- Clinical Global Impression–Severity Score (CGI-S) ≥ 4
- Stable Medication for tics and comorbidities for at least 30 days and during the study
- Prevention of pregnancy

Criteria for Exclusion

- Comorbidity when unstable and/or in need of an therapy
- Ongoing behavioral treatment for tics
- History of schizophrenia, psychotic, severe personality, pervasive developmental disorder, suicidal ideation with intent to act or a plan to act in the 12 months
- Current clinical diagnosis of substance abuse or dependence and compulsive disorder
- Secondary tic disorders
- Severe somatic diseases
- Pregnancy or lactation period
- Use of cannabis or cannabinoid-based medicine in the 30-day period prior to study entry

Methods
A total of 98 patients with TS or CTD were randomized across 6 study sites with a 2:1 ratio into a nabiximols and a placebo arm. The primary endpoint definition was defined as a reduction of at least 25% according to the YGTSS-TTS after 9 weeks of stable treatment. As a key secondary endpoint, in 2 study sites fitness to drive was investigated with respect to a non-inferiority margin of -32%. The primary as well as the key secondary analyses were performed with a center-stratified Mantel-Haenszel estimate for the risk difference (nabiximols – placebo). To examine effects on tics (as assessed by YGTSS-TTS) in specific subgroups at different time points, mixed linear models were used. Adverse and severe adverse events were analyzed.

Conclusion
Although the number of responders is larger in the nabiximols group compared to placebo, the CANNA-TICS study failed to demonstrate superiority. However, first results indicate that male patients and patients with ADHD benefit more than others. Most important for use of cannabinoids in clinical routine practice, the results suggest that fitness to drive was not impaired by use of nabiximols. Based on our data, nabiximols can be regarded as a safe treatment.

References

Fig. 1: Trial Flow

Fig. 2: Change from Baseline (YGTSS-TTS) (Least Square (LS) Mean Difference (Nabiximols – Placebo) derived from a Mixed Model Repeated Measures (ITT Population)

Fig. 3: Subgroup Analysis: Change from Baseline (YGTSS-TTS) Least Square (LS) Mean Difference (Nabiximols – Placebo) derived from a Mixed Model Repeated Measures (ITT Population)